国际肿瘤学杂志

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (4): 306-308.

• 论著 • 上一篇    下一篇

伊立替康和顺铂联合沙利度胺治疗复发性小细胞肺癌疗效研究

王军业, 胡东玉   

  1. 272029 济宁医学院附属医院肿瘤科
  • 出版日期:2013-04-08 发布日期:2013-03-27

Therapeutic effect of thalidomide plus irinotecan and cisplatin for recurrent small cell lung cancer

 WANG  Jun-Ye, HU  Dong-Yu   

  1. Department of Oncology，Affiliated Hospital of Jining Medical College, Jining 272029, China
  • Online:2013-04-08 Published:2013-03-27

PDF

1421

被引次数

6

摘要： 目的 探讨伊立替康和顺铂联合沙利度胺治疗复发性小细胞肺癌的疗效与不良反应。方法 选取同时期的62例复发性小细胞肺癌患者，按不平衡指数最小的分配原则随机分为观察组和对照组，观察组采用伊立替康和顺铂联合沙利度胺化疗；对照组采用常规伊立替康和顺铂化疗。比较两组患者疗效及不良反应。结果 观察组和对照组的客观有效率分别为86.7%和63.3%；两组临床疗效比较差异有统计学意义(χ2 =8.52，P＜0.05)；主要不良反应为血液学毒性和消化道症状，观察组和对照组比较差异无统计学意义(χ2 =0.18，P＞0.05)。结论 伊立替康和顺铂联合沙利度胺治疗复发晚期小细胞肺癌，有效率高，不良反应可以耐受。

关键词: font-size: 12pt, mso-bidi-font-family: 'Times New Roman', mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-ascii-font-family: 'Times New Roman'">肺肿瘤, 肿瘤复发, 药物疗法font-size: 12pt, mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体, mso-hansi-font-family: 宋体" lang="EN-US">, font-size: 12pt, mso-bidi-font-family: 'Times New Roman', mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-ascii-font-family: 'Times New Roman'">联合

Abstract: Objective To investigate the efficacy and toxicity of thalidomide plus irinotecan and cisplatin treatment for recurrent small cell lung cancer. Methods 62 patients with recurrent small cell lung cancer in the same period were randomly divided into observation group and control group according to the principle of minimum distribution imbalance index. The observation group patients were treated with thalidomide plus irinotecan and cisplatin chemotherapy, and the control group patients were treated  with irinotecan and cisplatin chemotherapy. The efficacy and toxicity of the two groups were compared. Results The overall response rate in the group observation was 86.7% compared with 63.3% in the control group, and the difference has statistical significance (χ2 =8.52，P<0.05). The major toxicities were hematologic toxicity and gastrointestinal symptoms, and the side effects was not statistically significant (χ2=0.18，P＞0.05). Conclusion The treatment of recurrent small cell lung cancer with irinotecan and cisplatin in combination with thalidomide has high efficiency, and the toxicity can be tolerated.

Key words: Lung neoplasms, Neoplasm recurrence, Drug therapy, combination